Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980040/S186

SENSAR 3-Piece Monofocal IOL, SENSAR 1-piece IOL, TECNIS Multi-focal 1-pc, TECNIS 1-PC OptiBlue IOL, TECNIS OptiBlue 1-P

Johnson & Johnson Surgical Vision, Inc. · Decision date Oct 19, 2026

MEDTECHLEDGER EXPLANATIONP980040/S186

What did the FDA decide?

The record covers PMA P980040, supplement S186, with a 30-day notice reason listed as a process change affecting manufacturer, sterilizer, packager, or supplier. The stated change is moving microbiology testing from an external contractor to an in-house laboratory supporting product manufacturing at the AMO Puerto Rico site. The listed devices are the SENSAR 3-Piece Monofocal IOL, SENSAR 1-piece IOL, TECNIS Multi-focal 1-pc, TECNIS 1-PC OptiBlue IOL and TECNIS OptiBlue 1-P, product code HQL, applicant Johnson & Johnson Surgical Vision, Inc.

S186 is a supplement to the existing PMA identified by the database, not a new approval of the whole lens system. The source states the intended purpose of the transfer; it does not report microbiology results, testing validation data or an independent finding of safety or effectiveness. The record also does not specify which lens models the in-house laboratory serves, the tests transferred, or the contractor involved.

The decision field reads OK30, dated 2026-10-19. Beyond that label and the notice reason, the supplied fields do not describe the decision's scope or any conditions.

FDA approval order statement

the transfer of microbiology testing from an external contractor to an in-house laboratory to support product manufacturing at the AMO Puerto Rico manufacturing site
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Oct 19, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P980040/S186
Regulatory pathway
PMA supplement
Product code
HQL
Decision code
OK30
Decision date
Oct 19, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: intraocular lens.

Product code
HQL
FDA device class
3

For the original device and its historical approval scope, see PMA P980040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P980040 · Original PMA

    SENSAR SOFT ACRYLIC UV-LIGHT ABSORBING POSTERIOR CHAMBER INTRAOCULAR LENS

  2. P980040/S186 received

    Application receipt date recorded by FDA.

  3. P980040/S186 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P980040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980040

Product / regulatory recordCompanyPathwayDecision dateSource
Johnson & Johnson Surgical Vision, Inc.PMA approvalFeb 3, 2000FDA

Explore the linked device profile

Other records with product code HQL

Product / regulatory recordCompanyPathwayDecision dateSource
Beaver-Visitec International, Inc.PMA supplementOct 27, 2026FDA
Carl Zeiss Meditec Production, LLCPMA supplementOct 23, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 23, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementOct 19, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 14, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Johnson & Johnson Surgical Vision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records